What if you could flip a genetic switch to silence a gene, then turn it back on with a simple drug? For researchers, gene-switch tools offer that kind of control—and a new system called Cyclone may ...

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell lung cancer (NSCLC) associated with EGFR exon 20 insertions, the agency said.

i have an issue with a very crowded sashimi plot of a whole gene that is difficult to read: this gets even worse if a add a white background to text. i know i could just zoom into the event, but i ...

Gram-negative bacterial infections are becoming an increasingly serious global health issue U.S. patent applications filed for three novel drug candidates: PKL200, TSL2200, and EAL2200 Continued ...

Zegfrovy (sunvozertinib) received accelerated FDA approval for NSCLC patients with EGFR exon 20 insertion mutations post-platinum-based chemotherapy progression. The Oncomine Dx Express Test was ...

Hello, I'm wondering if there's a setting or if other people have this issue as well (searching I could not find it). When we map with STAR, most of our data looks great. However, a small number of ...

Cell Biochemistry Section at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States; A key but often overlooked step in gene regulation is ...

Researchers of ancient Egypt discovered “five identical structures near the Khafre Pyramid’s base, linked by pathways, and eight deep vertical wells descending 648 meters underground.” Claims that ...

While working on a COVID-19-related project during the lockdown, Kärt Tomberg, PhD, found herself thinking about introns. She was part of a team working on the spike protein used in vaccines. Her task ...

On some level, biology is all about regulation, regulation, regulation. One way that our cells regulate their genes is through a process called alternative splicing, which entails the selective ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).